{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1466","upperLimit":"0.9473","value":"0.6000"},{"groupId":"OG001","lowerLimit":"0.0192","upperLimit":"0.4545","value":"0.1538"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Confirmed response rate will be estimated by the number of patients with an objective status of complete response, incomplete blood count recovery, nodular partial response, clinical complete response or partial response while on the combination therapy divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true overall response rate to the combination will be calculated. In addition, the responders on this study will be further examined in an exploratory manner to determine if there are any patterns in prognostic factors or disease characteristics, including whether the patient had a Richter's transformation or ibrutinib-resistant disease, for both single agent pembrolizumab and combination therapy responders.","dispersionType":"95% Confidence Interval","groups":[{"description":"CONTINUATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive idelalisib PO BID on days 1-21 OR ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 12 or 24 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator.","id":"OG000","title":"Arm A (Continuation Phase)"},{"description":"CONTINUATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive idelalisib PO BID on days 1-21 OR ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 12 or 24 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator.","id":"OG001","title":"Arm C (Continuation Phase)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"Confirmed All Response Rate of Patients Treated With Combination Therapy","type":"SECONDARY","unitOfMeasure":"proportion of participants"}